Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Rong Tao, MD) · rtao@shca.org.cn · 008621-64175590
Contact: Study coordinator (Wenhan Zhang, MD) · zhangwenhao@shca.org.cn · 008621-64175590

Study leads

Rong Tao, MD & PhD
Study Chair
Fudan University
Wenhao Zhang, MD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Changchun, China

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Diffuse Large B-Cell Lymphoma-Recurrent · Diffuse Large B-Cell Lymphoma-Refractory

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Sacramento, United States